- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Omnipod Insulin Management System
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Year to 8 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,221
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- G-CSF, Cisplatin, Etoposide, Irinotecan, Topotecan
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 79
- States / cities
- Lewes, Delaware • Newark, Delaware • Jacksonville, Florida + 59 more
- Conditions
- Depression
- Interventions
- S-citalopram, Cognitive behavioral therapy (CBT), TRODAT-1 single photon emission computed tomographic (SPECT) imaging
- Drug · Behavioral · Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Brain Metastases, Brain Cancer
- Interventions
- 18F-Fluciclovine
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 17 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
- Interventions
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Human Mesenchymal Stromal Cells, Cell Reconstitution Media
- Biological
- Lead sponsor
- Michael A. Matthay
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
- Conditions
- Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
- Interventions
- Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
- Drug
- Lead sponsor
- Food and Drug Administration (FDA)
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Loneliness, Social Isolation
- Interventions
- Virtual Yoga at First 8 weeks, Virtual Yoga at Second 8 weeks
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy
- Interventions
- K-877 CR Tablet A, K-877 CR Tablet B, K-877 CR Tablet E, K-877 IR Tablet
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Alcohol Consumption, Alcohol Use Disorder
- Interventions
- Step Away Chatbot, Step Away App
- Behavioral
- Lead sponsor
- University of Alaska Anchorage
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Anchorage, Alaska
- Conditions
- Major Depressive Disorder
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lung Transplantation, Chronic Lung Disease, Muscle Weakness, Rehabilitation
- Interventions
- IMT- Intervention group, IMT- Placebo group
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- PTSD
- Interventions
- Day 1 Assessments, Day 2 Fear Learning, Day 3 Fear Extinction, Moderate Intensity Exercise, Low Intensity Exercise, Day 4 Recall of Fear Extinction
- Other · Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 21 Years to 50 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Mild Traumatic Brain Injury
- Interventions
- Strategic Memory Advanced Reasoning Training, Traditional Cognitive Rehabilitation
- Other
- Lead sponsor
- The Defense and Veterans Brain Injury Center
- Federal
- Eligibility
- Not listed
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Oceanside, California
- Conditions
- Cardiovascular Disease
- Interventions
- Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray
- Dietary Supplement · Other · Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- ER-Positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Fulvestrant Run-In
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Cancer
- Interventions
- CT guided percutaneous ablation
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Leukemia, Acute Lymphoblastic, Small Lymphocytic Lymphoma
- Interventions
- Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine, Rituximab
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Sipuleucel-T, Lymph Node Biopsy
- Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stage IV Melanoma
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
- Biological
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more